Celltrion’s biosimilar ‘Herzuma’ proven in equivalence of efficacy with original
At the European Society for Medical Oncology(ESMO) symposium on the 9th(local time) in Madrid, Spain, Celltrion announced additional clinical trial results of 1-year safety of Herzuma(development name: CT-P6), an antibody biosimilar for the treatment of breast cancer, on early breast cancer patie...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.